Background: The motor protein myosin Va plays an important role in the trafficking of intracellular vesicles. Mutation of the Myo5a gene causes Griscelli syndrome type 1 in humans and the dilute phenotype in mice, which are both characterised by pigment dilution and neurological defects as a result of impaired vesicle transport in melanocytes and neuroendocrine cells. The role of myosin Va in platelets is currently unknown. Rab27 has been shown to be associated with myosin Va cargo vesicles and is known to be important in platelet dense granule biogenesis and secretion, a crucial event in thrombus formation. Therefore, we hypothesised that myosin Va may regulate granule secretion or formation in platelets.
Introduction
The unconventional, non-muscle, class V myosins play an important role in the transport of intracellular vesicles along actin filaments to membrane docking sites [1] . The isoform myosin Va has been shown to be crucial in the trafficking of melanosomes in melanocytes [2] and in the secretion of granules in neuroendocrine cells [3] . Mutations in the Myo5a gene lead to Griscelli syndrome type 1 in humans, a rare inherited autosomal recessive disorder characterised by hypopigmentation and neurological impairment [4] . In mice, myosin Va mutations result in the dilute phenotype with a lighter coat colour and lethal neurological defects [5] .
A variety of proteins involved in the regulation of granule transport has been described to interact with myosin Va. In melanocytes, the cargo-carrying C-terminal tail of myosin Va binds to the exophilin melanophilin [6, 7] which in turn interacts with Rab27 [8] , a GTP-binding protein of the Ras superfamily. Knockout of Rab27a/b in mice and Griscelli syndrome type 2 in humans, caused by mutation of the Rab27a gene, both show platelet defects resulting in increased bleeding times and a reduction in the number of dense granules, indicating that Rab27 is a key player in platelet dense granule biogenesis and secretion [9] [10] [11] [12] .
The secretion of intracellular granules from platelets is essential in the process of thrombosis. Upon activation, platelets release a wide array of mediators from their dense and a-granules [13] . Dense granules contain pro-aggregating factors, which sustain and enhance initial platelet responses. In addition to molecules involved in thrombus formation, a-granules also store a range of proteins and receptors involved in other patho-physiological processes, such as inflammation. As Rab27 is known to be associated with myosin Va cargo vesicles and myosin Va is highly expressed in both human and mouse platelets [14] , it is of great interest to determine the role of this motor protein in platelet granule secretion and formation.
In the present study, we used a novel targeted Myo5a gene deletion mouse model, which is non-lethal and shows no overt neurological phenotype. As shown by immunoblotting, myosin Va was undetectable in platelets from Myo5a 2/2 mice. Levels of surface proteins and granule counts were normal in Myo5a platelets. Contrary to our expectations, loss of myosin Va resulted in normal agonist-induced dense and a-granule secretion and unchanged numbers of dense and a-granules expressed. Furthermore, integrin a IIb b 3 activation, Ca 2+ signalling, and spreading on fibrinogen were not affected in Myo5a 2/2 platelets. These results establish that myosin Va is not required for most platelet responses, including dense and a-granule secretion.
Methods

Materials
The myosin Va antibody (#3402) was from Cell Signaling Technology (Danvers, MA, USA). The myosin Vb antibody (18) , the myosin Vc antibody (Y-19), and the GAPDH antibody (6C5) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The myosin VI antibody (ABT42) was from Millipore (Temecula, CA, USA). Horseradish peroxidase (HRP)-conjugated donkey anti-rabbit, anti-mouse and anti-goat secondary antibodies were from Jackson ImmunoResearch Laboratories (Newmarket, UK). FITC-P-selectin and PE-JON/A antibodies were from Emfret Analytics (Eibelstadt, Germany). FITC-LAMP1 (1D4B) antibody was from Abcam (Cambridge, UK). NuPAGE LDS sample buffer was obtained from Invitrogen (Carlsbad, CA, USA). 106 blocking buffer and TRITC-phalloidin were from SigmaAldrich (Poole, UK). Fura-PE3 was from Teflabs (Austin, TX, USA). Luciferin-luciferase was from Chronolog (Labmedics, Stockport, UK). AYPGKF-NH 2 (PAR4 activating peptide) was from Bachem (Weil-am-Rhein, Germany). CRP (cross-linked collagen-related peptide) was synthesized by Prof Richard Farndale (Department of Biochemistry, University of Cambridge, UK).
Mouse platelet preparation
A colony of Myo5a 2/2 mice was obtained from the Wellcome Trust Sanger Institute (Cambridge, UK), which were mated with C57/Bl6j mice (Charles River, UK) to generate Myo5a +/2 . These mice were crossed to generate Myo5a 2/2 mice and littermate Myo5a +/+ mice, which were used as control (wild-type, WT). Use of mouse platelets was approved by local research committee at the University of Bristol, UK, and mice were bred for this purpose under UK Home Office Licence PPL30/2908 held by Alastair W. Poole. Blood was drawn and washed platelets were prepared as described previously [15] . In brief, blood was drawn by cardiac puncture under terminal anesthesia into sodium citrate (4%; 1:10 v/v). Blood was diluted with modified Tyrode's-HEPES buffer (134 mM NaCl, 2.9 mM KCl, 20 mM HEPES, 5 mM glucose, and 1 mM MgCl 2 , pH 7.3) and centrifuged at 180 g for 6 minutes at room temperature. Platelet-rich plasma was removed, and platelets were isolated by centrifugation at 550 g for 6 minutes in the presence of PGE 1 (140 nM) and apyrase (0.02 U/ml). Pelleted platelets were resuspended to the required density in modified Tyrode's-HEPES buffer and rested for 30 minutes at 37uC in the presence of 0.02 U/ml apyrase prior to stimulation. No indomethacin or other cyclooxygenase inhibitors were added during platelet preparation. Unless otherwise indicated, 1 mM CaCl 2 was added immediately prior to stimulation.
Electrophoresis and Western blotting
Washed platelets (2610 8 /mL) were lysed in NuPAGE LDS sample buffer which was supplemented with 50 mM dithiothreitol. Samples were separated by electrophoresis on 6% Bis-Tris polyacrylamide gels. Proteins were then transferred to polyvinylidene difluoride membranes which were blocked with 16 blocking buffer and probed with specific primary and HRPconjugated secondary antibodies. Proteins were detected using ECL reagents.
Subcellular morphology
Subcellular morphology of WT and Myo5a 2/2 platelets was analysed by transmission electron microscopy (TEM). Platelet-rich plasma was collected and spun at 590 g for 5 minutes. Supernatant was removed from the platelet pellet, and the pellet was fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (PB) (pH 7.4). The pellet was washed in PB and then incubated in 1% osmium tetroxide in PB for 30 minutes. After washing in PB and deionized water, the pellet was incubated in 3% uranyl acetate in deionized water for 30 minutes. After washing with deionized water, the pellet was dehydrated in a graded series of increasing amounts of ethanol (70%, 80%, 90%, 96%, 100%, and 100%, with each step lasting for 10 minutes). After removal of the 100% ethanol, the pellet was incubated with pure Epon for 2 hours at room temperature. Thereafter, the Epon was replaced with fresh Epon, and this was hardened overnight in a 60uC oven. Ultrathin counterstained sections were imaged on a Philips CM100 equipped with a side-mount MegaView III camera (Olympus Soft Imaging Solutions).
To determine the dense-granule and a-granule content, total numbers of granules in equivalent-sized fields of view were counted. For each genotype, 10 randomly chosen fields of view were examined. All microscopic images were taken at the same magnification, and the number of cells per field of view was equivalent between WT and Myo5a 2/2 preparations. The number of dense granules and a-granules is expressed as the mean number per platelet slice. This approach allows the number of each granule type to be compared between WT and Myo5a 2/2 platelets, although since individual thin sections of platelets are imaged, the number of granules seen is substantially fewer than the total number of granules in individual platelets.
Dense granule secretion
The release of ATP from dense granule release was assessed luminometrically, as previously described [15] . Briefly, platelets were incubated with Chrono-Lume luciferase-luciferin reagent before stimulation with the indicated concentration of agonist. ATP secretion was measured as an increase in luminescence.
Integrin a IIb b 3 activation and a-granule secretion Washed platelets (5610 7 /mL; 32 mL) were incubated fluorescein isothiocyanate (FITC)-labelled anti-P-selectin antibody, phycoerythrin (PE)-labelled JON/A antibody (4 mL of each), and agonist (4 mL; 1:10 dilution) for 10 min under non-stirring conditions. Platelets were then fixed with paraformaldehyde (2%). Two-colour analysis was conducted by flow cytometry on a FACSCalibur flow cytometer (BD Biosciences), using CellQuest version 3.1f software (BD Biosciences). The platelet population was identified by forward and side scatter profile.
To assess the timecourse of a-granule secretion, platelets were stimulated for the indicated time with AYPGKF (300 mM) prior to fixation. FITC-labelled anti-P-selectin was added for the final 30 s of stimulation.
Lysosome secretion
Washed platelets (5610 7 /mL; 36 mL) were incubated FITClabelled anti-LAMP1 antibody (4 mL), and agonist (4 mL; 1:10 dilution) for 10 min under non-stirring conditions. Platelets were then fixed with paraformaldehyde (2%). FITC fluorescence was analysed by FACS analysis as above.
Ca
2+ signalling
Changes in cytosolic [Ca 2+ ] i were measured by spectrofluorometry in washed suspensions of platelets (1610 8 /mL) loaded with the Ca 2+ -senstive dye, Fura-PE3, as described previously [16] . Platelets were stimulated at 37uC with continuous stirring. ] i as previously described [16] . Ionomycin (1 mM) was added in the presence of the calcium chelator EGTA (1 mM). Alternatively, platelets were stimulated with the indicated concentrations of CRP in the presence of 1 mM CaCl 2 .
Platelet spreading
Coverslips were coated with fibrinogen (100 mg/ml). Washed platelets (2610 7 /mL) were dispensed onto the coverslip for 1 hr. Where indicated, platelets were stimulated with AYPGKF (300 mM) for 1 min prior to adhesion. Adherent platelets were fixed with paraformaldehyde (4%), permeabilised with Triton X-100, and stained with TRITC-phalloidin. Adhesion and spreading of platelets was observed by fluorescence microscopy using a cooled CCD camera attached to a Leica DM IRB inverted epifluorescence microscope with a 636 objective. Ten images were taken in different random parts of the coverslip area and analysed using ImageJ software. Platelets were scored as being completely unspread with no filopodia (''no spreading''), having filopodia, having both filopodia and partial lamellipodia (''some spreading''), or having a full lamellipodium (''full spreading'') and expressed as a proportion of the total number of platelets in the image. The proportions of each morphology in each of the ten images were then averaged. This analysis was performed separately on platelets from 3 WT mice and 3 Myo5a 2/2 mice.
Statistics
Where presented, mean data are given 6 SEM. Statistical significance was determined by 2-way ANOVA with Bonferroni post-test, performing using Prism 4.0 (GraphPad Software). P,0.05 was considered significant.
Results and Discussion
Selective depletion of myosin Va from mouse platelets
To evaluate the function of myosin Va in platelets, Myo5a 2/2 mice were obtained from Wellcome Trust Sangar Institute (Cambridge, UK), in which the gene encoding this protein (Myo5a) had been disrupted by homologous recombination in embryonic stem cells, and the cells were used to generate gene-targeted mice by standard techniques (Fig. 1A) . Myo5a 2/2 mice were viable and healthy, but showed a lighter grey coat colour compared to wildtype controls (Fig. 1B) , similar to the hypopigmentation which is seen in the dilute mice. This suggests that our mice are likely to have a similar defect in Myo5a-dependent melanosome trafficking to dilute mice [5] . Mice were not obtained in their expected Mendelian ratios (Fig. 1C) . Of 130 offspring genotyped, 48 were wild-type (37.5%), 63 were heterozygous (49.2%) and only 17 were Myo5a 2/2 (13.3%). Low generation of Myo5a 2/2 mice was seen in both male and female offspring. Myo5a 2/2 mice exhibited normal platelet count and mean platelet volume ( Fig. 1D and E) . Other haematological parameters, specifically the red blood cell count, haematocrit, mean corpuscular volume and white blood cell count, were also within the normal range (data not shown).
As demonstrated by immunoblotting, myosin Va (207 kDa) was not detected in Myo5a 2/2 platelets, whereas it was expressed in wild-type mouse platelets as well as in human platelets (Fig. 1F) . Myo5a 2/2 platelets had normal levels of surface-expressed CD41, glycoprotein (GP) VI and GPIb (Fig. 1G) . Thus, Myo5a 2/2 platelets provided us an ideal opportunity to study platelet function in the selective absence of myosin Va.
Platelet granule biogenesis and secretion are unaffected by loss of myosin Va
Since Rab27 regulates dense granule formation and secretion in platelets [10] and has been shown to interact with myosin Va in melanocytes [8] , we investigated whether myosin Va is also involved in platelet dense granule formation and secretion. Subcellular morphology of platelets from WT and Myo5a 2/2 mice was examined by TEM ( Fig. 2A) , and visible granules counted (and normalized to the number of platelets in the field of view; Fig. 2B ). Both dense and a-granule counts in each thin section were similar to wild-type, suggesting that myosin Va is not involved in platelet granule biogenesis.
Dense granule secretion of ATP, monitored by luminometry, was stimulated by a range of concentrations of the GPVI agonist, collagen-related peptide (CRP) or the thrombin receptor PAR4 agonist, AYPGKF. However, no difference in ATP secretion was observed between wild-type and Myo5a 2/2 platelets at any concentration tested (Fig. 3A) . This indicates that myosin Va is not required for the secretion of dense granule content.
Next, we addressed whether myosin Va has a role in a-granule secretion. By flow cytometric analysis, P-selectin expression on the platelet surface was assessed. P-selectin surface expression induced by various concentrations of CRP and AYPGKF was not significantly affected in Myo5a 2/2 platelets compared to wild-type (Fig. 3B) , suggesting that myosin Va is not required also for agranule secretion in platelets. In addition, analysis of the time course of a-granule secretion indicated that the rate of P-selectin expression was not different between wild-type and Myo5a 2/2 platelets (Fig. 3C) .
Finally, we investigated whether myosin Va regulates lysosome secretion by assessing agonist-induced surface expression of LAMP1, which correlates with lysosomal enzyme release. Platelet activation induced an increase in surface LAMP1. This was not different between WT and Myo5a 2/2 platelets, indicating that lysosome secretion is not affected by loss of myosin Va. Taken together, these data show that myosin Va has no non-redundant role in granule secretion in mouse platelets.
There are several possible explanations for these data. It is possible that myosin Va genuinely plays no role in granule secretion in platelets, despite a role for Rab27. This could reflect the small size of the platelet, and its extensive plasma membraneassociated target membrane system, the open canalicular system. This is comprised of multiple invaginations of the membrane, forming target sites for fusion of exocytotic vesicles throughout the cell. Effectively, this may mean that the majority of secretory vesicles may already be in a primed and docked position, and that there is no need for myosin-dependent trafficking. It might however be assumed that vesicles require trafficking to platelets within the megakaryocyte, and therefore that myosins may be required for this step. However, data from Fig. 2A and 2B show that these platelets contain normal numbers of both a-granules Figure 7 . Loss of myosin Va does not affect platelet spreading on fibrinogen. Wild-type and Myo5a 2/2 mouse platelets were dispensed onto fibrinogen-coated coverslips for 1 h. Where indicated, platelets were stimulated with the PAR4 agonist AYPGKF (300 mM) for 1 min prior to adhesion. Cells were stained with TRITC-phalloidin. In (A), representative images are shown (n = 3). (B) Platelet morphological subtypes were counted and fractions (mean +/2 SEM, n = 3) were calculated. doi:10.1371/journal.pone.0053239.g007
and dense granules and therefore that myosin Va expression is also not required for normal trafficking and packaging of secretory granules into platelets at the level of the megakaryocyte. It is likely that, for this role, myosin II is the predominant motor protein involved [17, 18] .
On the other hand, it is also possible that other related myosins are expressed or over-expressed in the Myo5a 2/2 platelet, and that redundancy of function with these myosins is such that there is no observable phenotype in the single Myo5a 2/2 mouse. Myosin Vb is involved actin-dependent vesicle transport and plasma membrane recycling in various cells, including neurons and oocytes [19] [20] [21] . Myosin Vc localises with membrane compartments involved in transferrin trafficking in epithelial cells [22] and has been shown to function as a molecular motor driving secretory granule transport in lacrimal gland acinar cells and the MCF-7 cell line [23, 24] . To examine the expression of myosin Vb, Vc, and VI, we immunoblotted for these proteins in human, wild-type, and Myo5a 2/2 platelets (Fig. 4) . Myosin Vb and Vc could not be detected in any platelet sample, suggesting that the absence of a platelet defect in myosin Va-deficient mice is not a consequence of normal expression or compensatory upregulation of myosin Vb or Vc. The absence of these proteins is consistent with mRNA analysis of human and mouse platelets [14] .
Recently, it has been found that myosin VI regulates fusion pores formed between secretory vesicles and the plasma membrane [25] . In contrast to myosin Vb and Vc, myosin VI was present in human, wild-type and Myo5a 2/2 platelets. There was no upregulation of myosin VI detected in myosin Va-deficient platelets, suggesting that its expression does not change in the absence of myosin Va. However, the presence of myosin VI in platelets, and its recently reported role in exocytosis, provides the possibility that this protein is involved in platelet granule secretion, and that there may be redundancy of function between this motor protein and myosin Va in the control of granule secretion. This may be more important in mouse platelets than in human platelets, as mRNA analysis indicates a greater abundance of myo6 mRNA in mouse platelets [14] . The possible role of myosin VI in mouse platelet exocytosis deserves further attention.
Myo5a
2/2 platelets show normal integrin a IIb b 3 activation, Ca 2+ signalling and spreading
It was important also to investigate whether myosin Va plays a role in other platelet responses. Integrin a IIb b 3 activation was assessed by using the activation-specific antibody, Jon/A. CRP or AYPGKF induced integrin a IIb b 3 activation in wild-type and Myo5a 2/2 platelets with no significant differences over a range of concentrations of agonists (Fig. 5) .
Myosin Va transports extensions of the ER into dendritic spines of Purkinje neurons, forming a local Ca 2+ store that is required for local Ca 2+ release [26] . We tested therefore whether myosin Va also transports Ca 2+ stores into platelets during thrombopoiesis. Mouse platelets were loaded with the Ca 2+ -sensitive dye, Fura-PE3. Rapid depletion of the intracellular Ca 2+ stores by ionomycin produced a transient increase in [Ca 2+ ] i that was not significantly different in Myo5a 2/2 platelets (Fig. 6A) . Furthermore, Ca 2+ signals in response to a range of concentrations of CRP were not significantly altered (Fig. 6B) . These data suggest that myosin Va is not required to transport intracellular Ca 2+ stores into platelets, since the stores are equivalently loaded with releasable calcium, and is not involved in agonist-induced Ca 2+ signalling in platelets. Finally, we analysed whether loss of myosin Va affects platelet spreading on a fibrinogen-coated surface. Myo5a 2/2 platelets did not show a difference in spreading on this surface whether in presence or absence of stimulation with AYPGKF (Fig. 7A) . Morphological analysis also did not reveal any difference in subtype fractions (no spreading, filopodial, some spreading or full spreading) between myosin Va-deficient and wild-type platelets (Fig. 7B) .
We conclude therefore that although myosin Va has been shown to be critical in intracellular actin-dependent vesicle transport in melanocytes and neuroendocrine cells, our data demonstrate that this motor protein is not required for mouse platelet granule secretion and other aspects of mouse platelet function. This contrasts to the important role for Rab27a/b in platelet dense granule biogenesis and secretion [9] [10] [11] , and suggests that Rab27 proteins act through effectors other than myosin Va. One such effector is Munc13-4, which is essential for platelet dense granule secretion [27] [28] . However, since Munc13-4-deficient platelets have normal granule numbers [27] , there is likely to be another Rab27 effector that is involved in granule biogenesis that remains to be described.
